TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film FreezingBusiness Wire • 09/24/20
TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical TrialBusiness Wire • 09/15/20
TFF Pharmaceuticals to Participate in Anti-fungal Webinar Presented by Maxim Group LLC on September 17th, 2020Business Wire • 09/14/20
TFF Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceBusiness Wire • 09/10/20
TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/14/20
UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.PRNewsWire • 08/13/20
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamideBusiness Wire • 08/13/20
TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business ResultsBusiness Wire • 08/13/20
TFF Pharmaceuticals Announces $25.9 Million in Financing to Further Advance Its Thin Film Freezing Technology PlatformBusiness Wire • 08/11/20
TFF Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 13, 2020Business Wire • 08/04/20
TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical TrialBusiness Wire • 07/30/20
TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral TreatmentBusiness Wire • 07/29/20
TFF Pharmaceuticals' (TFFP) CEO Glenn Mattes on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/15/20